Drug Profile
IMM 529
Alternative Names: IMM-529Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Immuron
- Class Anti-infectives; Polyclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Clostridium difficile infections
Most Recent Events
- 22 Dec 2023 Immuron announces intention to submit pre-IND information package to the US FDA for Clostridium difficile infections in first half of 2024
- 22 Jun 2023 Immuron to proceed with US FDA pre-IND submission for IMM 529
- 17 Jan 2023 Immuron receives compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile infections patent in European Union